Safety and Efficacy of Drug-Coated Balloon for Peripheral Artery Revascularization—A Systematic Review and Meta-Analysis

Abstract

A review of randomized controlled trials and observational cohort studies found in the PubMed, Embase, and Cochrane databases through April 2021. In 26 studies comprising 26,845 patients who were treated by uncoated balloon (UCB) (17,770) or drug-coated balloon (DCB) (9075) angioplasty for lower extremity peripheral arterial disease (LE-PAD), DCB was associated with significantly lower vessel restenosis, reduction in major amputation, and decreased need for repeat target lesion revascularization compared with UCB. Primary patency rate was significantly higher in patients who underwent DCB angioplasty. Odds for all-cause mortality were not significantly different between the two groups. The use of DCB in LE-PAD intervention is associated with higher primary patency, lower restenosis, lower amputation rate, and decreased need for repeat revascularization with similar all-cause mortality as compared with UCB.